Precision Medicine for Immunotherapy-Resistant Advanced Esophageal Cancer

NCT07653451 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

NOT_YET_RECRUITING

Status

90

Enrollment

OTHER

Sponsor class

Conditions

Esophageal Squamous Cell Carcinoma

Interventions

DRUG: Afatinib + Toripalimab
DRUG: Dalpiciclib + Pyrotinib
DRUG: Camrelizumab + Apatinib

Sponsor

Peking University Cancer Hospital & Institute